Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS; Chandrikha Chandrasekharan, MBBS
- Alexandria May, PharmD, BCPS
- Chandrikha Chandrasekharan, MBBS
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO
Optimizing Treatment Intensity in Early-Stage TNBC
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®
Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
- Roberto Leon-Ferre, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
1.50 credits
MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits

Medical News

Medical News
COLOR III Short-Term Outcomes: taTME vs Laparoscopic TME
06/05/2026
Read more
Medical News
Savolitinib In Met-Amplified Gastric Or GEJ Adenocarcinoma
06/05/2026
Read more
Medical News
Perioperative Apalutamide Cuts Metastasis Risk in Proteus Trial
06/05/2026
Read more
Medical News
Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
06/05/2026
Read more

CME/CE

Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
MinuteCE®
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Adam J. Luginbuhl, MD; Jennifer Johnson, MD, PhD
0.50 program credits
- Adam J. Luginbuhl, MD
- Jennifer Johnson, MD, PhD
0.50 program credits
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME/CE
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
CME/CE
コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
Barbara O'Brien, MD
0.25 credits
- Barbara O'Brien, MD
0.25 credits

Clinical Practice

Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Matching TNBC Treatment Intensity to Patient Needs
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®
Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
- Roberto Leon-Ferre, MD

Programs

Assessing and Interpreting pCR in Perioperative NSCLC
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD; Alexander Spira, MD, PhD, FACP
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
- Amy Comander, MD
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
- Daniel Hertz, PhD, PharmD
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
MinuteCE®
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits